Back to all Current clinical trials
Back to all Current clinical trials
Medicinal cannabis for palliative care patients - exploring detection of cannabis in saliva, urine and blood tests.
Advanced Cancer
This study explores the detection of cannabis in saliva, urine and blood tests in advanced cancer patients taking CBD-dominant medicinal cannabis products. Patients will take a cannabis product that mostly contains CBD with small amounts of THC (the ingredient responsible for intoxication). Saliva, urine and blood will be regularly tested for THC to determine how strongly it is detected and for how long tests remain positive after patients stop taking the medication.
- Category
-
Trial status
Recruiting
-
Trial phase
Phase 4 Drug TrialTrials of approved medications to provide “real world evidence” of efficacy and safety in clinical practice.
Trial contact details
-
Contact person
Mater Palliative and Supportive Care Research
-
Phone
0434 856 156
What you need to know
Who can take part?
- People over 18 years old with advanced cancer
- People receiving standard palliative care
- People who are willing to not drive for the entirety of the trial
- People who test negative for THC at the beginning of the trial and agree not to use any other cannabis products until the trial is complete
- People without a history of psychiatric or substance use disorders
- People without severe liver or kidney impairment
- People who are not pregnant and who agree to avoid pregnancy until at least 12 weeks after the trial
What is involved for you?
- Taking study medication for 4 weeks
- Face-to-face visits each week
- Regular phone calls with research nurses
- Giving blood and urine samples
- Testing saliva at home with provided kits
- Medical assessments and questionnaires
Trial dates
This trial is accepting participants until December 2024.
